The vacuolar-ATPase (v-ATPase) is a proton transporter found on many intracellular organelles and the plasma membrane (PM). The v-ATPase on PMs of cancer cells may contribute to their invasive properties in vitro. Its relevance to human cancer tissues remains unclear. We investigated whether the expression and cellular localization of v-ATPase corresponded to the stage of human pancreatic cancer, and its effect on matrix metalloproteinase (MMP) activation in vitro. The intensity of v-ATPase staining increased significantly across the range of pancreatic histology from normal ducts to pancreatic intraepithelial neoplasms (PanIN), and finally pancreatic ductal adenocarcinoma (PDAC). Low-grade PanIN lesions displayed polarized staining confined to the basal aspect of the cell in the majority (86%) of fields examined. High-grade PanIN lesions and PDAC showed intense and diffuse v-ATPase localization. In pancreatic cancer cells, PM-associated v-ATPase colocalized with cortactin, a component of the leading edge that helps direct MMP release. Blockade of the v-ATPase with concanamycin or short-hairpin RNA targeting the V 1 E subunit reduced MMP-9 activity; this effect was greatest in cells with prominent PM-associated v-ATPase. In cells with detectable MMP-2 activities, however, treatment with concanamycin markedly increased MMP-2's most activated forms. V-ATPase blockade inhibited functional migration and invasion in those cells with predominantly MMP-9 activity. These results indicate that human PDAC specimens show loss of v-ATPase polarity and increased expression that correlates with increasing invasive potential. Thus, v-ATPase selectively modulates specific MMPs that may be linked to an invasive cancer phenotype.
Cancer cells often exist in hypoxic conditions owing to unchecked growth and a deficient blood supply. 1 The acidic tumor microenvironment that results from hypoxia evokes compensatory changes in the cancer cell that confer survival and growth advantages. One such mechanism is the activity of the vacuolar-ATPase (v-ATPase). 2, 3 This ubiquitous proton transporter mediates multiple pH-dependent intracellular processes including vesicular trafficking, coupled ion gradient-molecular transport, and protease activation. [4] [5] [6] [7] The v-ATPase was originally characterized in association with intracellular organelles, but is now also recognized as a component of plasma membranes (PMs) that mediates proton extrusion in some normal and malignant cells. [8] [9] [10] [11] In breast cancer cells, the abundance of v-ATPases on the PM correlates with an invasive phenotype. 11 Further, v-AT-Pase inhibitors reduce cell migration in cancer cells with high levels of PM v-ATPase. 11 It has been postulated that cell surface v-ATPase activity can provide a localized proton flux creating an acidic extracellular microenvironment. 3 One potential effect of this activity is to optimize pH for extracellular protease activation, thereby facilitating matrix degradation and cellular invasion.
The v-ATPase is comprised of two large, multi-subunit complexes organized into a soluble domain (V 1 ) responsible for ATP hydrolysis and a membrane-bound domain (V 0 ) that forms the pore allowing for proton transport across membranes. 12 Multiple isoforms of the 'a' subunit that comprise the V 0 complex exist. Distinct V 0 a isoforms are thought to be critical for targeting the V 0 complex to distinct cellular membranes. For example, the V 0 a3 subunit on apical PMs of osteoclasts generates the acidic extracellular microenvironment required for bone resorption. 13, 14 Mutations in V 0 a3 result in the human autosomal recessive disease, osteopetrosis, which is characterized by excess bone and severely impaired osteoclast activity. 15, 16 A mouse model of V 0 a3 deletion results in severe skeletal deformities and early death, and can be averted by V 0 a3 gene restoration. 17, 18 In breast cancer cells, the V 0 a3 and V 0 a4 isoforms were also recently shown to be essential for cellular invasion. 19 These findings show that specific V 0 a isoforms provide a mechanism to target v-ATPase activities to the cell surface and affect cell function. These findings suggest that differences in the v-ATPase localization assessed by immunolabeling could be used to predict the behavior of cancer types, and that its use in clinical specimens could serve as a histological marker of aggressiveness.
Expression and localization of v-ATPase in human cancer specimens has not been extensively explored. To determine whether elevated v-ATPase staining corresponds to the invasive phentoype in human pancreatic cancer, we assessed the range of tissues from non-invasive pancreatic intraepithelial neoplasia (PanIN) lesions to pancreatic ductal adenocarcinoma (PDAC). Here, we report that the v-ATPase in human PDAC loses its polarity with increasing invasive potential. Furthermore, we observed that select v-ATPase isoforms are found on human pancreatic cancer cells, and that the v-AT-Pase localizes with known components of the cellular invasion apparatus and has functional effects on matrix metalloproteinase (MMP) activation.
MATERIALS AND METHODS Human Tissue
Archival specimens were obtained from patients who underwent surgery for a diagnosis of PDAC. The pathological diagnosis confirmed PDAC in all cases (n ¼ 16). Fifty random normal ducts, PanIN lesions, and PDAC lesions were evaluated independently by two pathologists (SEC, PF). Intensity of staining was scored as 1 þ (mild), 2 þ (moderate), or 3 þ (intense). Immunolabeling was characterized as basal, mixed basal/apical, or mixed basal/diffuse. The Institutional Review Board of the VA CT Healthcare System approved the study.
Antibodies and Reagents
Antibodies to V 1 E (Genway), V 0 a2 and V 0 a3 (gift from Dr Beth S Lee, Ohio State School of Medicine) were used to assess v-ATPase isoform specificity. Antibodies to cell surface markers E-cadherin (BD Biosciences) and epidermal growth factor receptor (Cell Signaling) were used to delineate localization of v-ATPase on PMs. An anti-cortactin antibody (AbCam) was used to mark cellular invasive fronts. 20, 21 Secondary fluorescent antibodies were purchased from Invitrogen. Chemical reagents were purchased from Sigma.
Cell Culture
The human pancreatic cancer cell lines Panc-1, MiaPaCa, and BXPC3 were maintained according to ATCC guidelines. As v-ATPase assembly is glucose dependent, 22,23 DMEM with low (1 g/l) and high (4.5 g/l) glucose were used to assess the role of v-ATPase on protease activation. To obtain conditioned medium (CM), cells were grown to 80% confluence, washed twice with serum-free media, and then incubated with serum-free media overnight. CM was obtained after 18-20 h and concentrated approximately 40-fold using Amicon Ultra centrifugal filters (Millipore) with a 10 kDa cutoff.
Short-Hairpin RNA Knockdown of V-ATPase Subunit, V 1 E Oligonucleotide targeting sequences corresponding to the coding regions of human V 1 E were annealed and ligated into pSuper.retro.puro (Oligoengine) (Supplementary Table 1 ). Panc-1 cells were transfected with adeno-associated viral vector and transfected clones selected with puromycin (1-2.5 mg/ml). Surviving clones were maintained in puromycin 2.0 mg/ml. After immunoblotting V 1 E, percent knockdown was assessed by densitometry using the NIH Image J software.
Immunohistochemistry and Immunofluorescence
Immunohistochemistry was performed as described. 24 Sections were deparaffinized, treated to inhibit endogenous peroxidase, and subjected to antigen retrieval. Slides were washed in tris-buffered saline and incubated with primary antibodies. Sections were washed, incubated with biotinylated anti-serum, and then with streptavidin complexed with horseradish peroxidase followed by diaminobenzidine. Sections were then counter-stained with hematoxylin and eosin.
For immunofluorescence labeling, pancreatic cancer cells were grown on methanol-treated coverslips. Cells were rinsed with phosphate-buffered saline, permeabilized with 0.05% saponin for 15 min, and blocked in 3% BSA. Coverslips were incubated with primary antibody, and then corresponding secondary antibodies. Slides were mounted with Prolong Gold with DAPI (Invitrogen). Control slides were incubated in secondary antibody only. Slides were examined with a Zeiss Axiophot immunofluorescence microscope. Images were obtained with SPOT software and overlay images obtained using Adobe Photoshop, version 9.0.
Zymography and Immunoblotting
MMPs were first cloned as cancer-specific genes and play a critical role in tumor invasion and metastases. 25 To detect MMP-2/9 activities in pancreatic cancer secretions, zymography was performed using commercial (Invitrogen) 10% gelatin-containing gels. Briefly, 10-20 mg of cellular proteins were subject to non-denaturing electrophoresis as described. 26 Gels were washed in 2.5% Triton X-100 and then incubated in developing buffer. After Coomassie blue staining, gels were destained and the amount of MMP activity detected as clear bands was analyzed by densitometry. The purified intermediately active form (66 kDa) of MMP-2 (5-10 ng; Calbiochem) was used as a positive control. Optimal incubation times were as follows: Panc-1 (12-16 h); MiaPaCa (18-24 h); and BXPC3 (6-8 h), n ¼ 4 experiments per group. The protease activity was estimated using the NIH Image J software as follows: a measurement box was placed over cleared areas of degradation and the immediate nondegraded background. Values were normalized to the highest density and comparisons were made within low and high glucose conditions, and then across the different glucose concentrations.
Immunoblotting was performed as described. 24 Protein content was determined by Bradford assay. After blocking in a 5% milk solution, membranes were incubated overnight with antibodies to PEDF. After washing in TBS and 0.05% Tween, the primary antibody was labeled using a peroxidaseconjugated goat anti-rabbit IgG. Peroxidase was detected by a chemiluminescence assay (Pierce). Equivalence of loading was confirmed using b-actin (Sigma) or Coomassie stain of CM.
Invasion and Migration Assays
An agarose-spot assay assessing cellular invasion number and depth was performed as described. 27 Agarose spots were plated on recessed collagen-coated cell culture plates in the presence of epidermal growth factor (R&D Systems) at a final concentration of 30 ng/ml. Cells were plated for 4-6 h and allowed to adhere in the presence of normal growth medium. The medium was then changed to serum-free media for 12-24 h in the absence and presence of concanamycin 50 nM. Cells that were able to invade across the outer rim of the agarose spot were counted as positive. Ten randomly selected fields under 10 Â for each condition were visualized.
Wound migration assays were performed as described. 11 In brief, a 2 mm horizontal wound was created after cells were grown to confluence. The cells were washed and placed under serum-free conditions in the absence and presence of concanamycin (50 nM). Cells were evaluated at 24-48 h for migration across the wound. Cells were fixed and 10 random images were captured. In each image, three random measurements of the diameter were carried out using the NIH Image J software, averaged, and values normalized based on the largest diameter. Assays were carried out in triplicate.
Statistical Analysis
P-values were calculated using two-tailed Student's t-tests on Prism software version 4.0, with Po0.05 deemed statistically significant. For differences in immunohistochemistry density, one-way analysis of variance was used. Values were stated as mean±s.e.m. or s.d.
RESULTS

Human PDAC Tissues Show Increased V-ATPase Levels and Loss of Polarity with Advancing Neoplastic Features
Histological analysis from normal ducts through PanIN lesions and finally to PDAC showed distinct patterns of V 1 E subunit staining that differed in intensity and distribution. In the absence of a primary antibody, there was little labeling (Figure 1a ). Using an antibody targeting the V 1 E subunit, normal ducts ( Figure 1b ) displayed weak staining with a mixed basal/apical (estimated average ratio intensity to negative control: 1.24 ± 0.43) pattern. Low-grade PanIN (Figure 1c ) lesions showed a typical columnar appearance with basally oriented nuclei, an increased N/C ratio, and the presence of mild nuclear atypia. These lesions showed more intense v-ATPase immunoreactivity than normal ducts (intensity: 1.72 ± 0.45). Further, low-grade PanIN lesions revealed striking differences in the distribution of v-ATPase E subunit compared with apical and basal staining in normal ducts. Thus, in 86% of the fields, labeling in low-grade PanIN lesions was basally oriented with the remaining 14% showing mixed basal/apical distribution. High-grade PanIN ( Figure  1d ) lesions displayed even more intense cellular labeling than the lower grade lesions (intensity: 2.56±0.50), but its distribution was more diffuse than observed with lower grade lesions. (Additional images contrasting low-grade from highgrade PanIN are provided in Supplementary Figure 1 .) PDAC (Figures 1e-g) , whether from the primary tumor (Figure 1e ), or metastatic to lymph nodes ( Figure 1g ) showed uniformly intense staining and diffuse labeling. Finally, as endothelial and stromal cells release proteases and contribute to tumor spread, areas of stroma were also examined for v-ATPase labeling. Positive V 1 E labeling that corresponded to vascular structures (Figure 1h , circular areas) or spindle-shaped cells that likely reflect fibroblasts (Figure 1h , arrows) was present in tumor-associated stroma, but not in stroma adjacent to normal ducts ( Figure 1b ). Findings from our histological analysis are summarized in Table 1 . These results indicate a significantly increased intensity (Po0.001) and a loss of v-ATPase polarity that occurs from low-grade PanIN to invasive PDAC. The findings are consistent with in vitro studies that illustrate v-ATPase function is necessary for cancer cell homeostatic and invasive properties. 11, 19 Pancreatic Cancer Cells Display V-ATPase Localization and Colocalize with Components of Cellular Invasion Analogous to studies in other cancer cells, 11, 19 v-ATPase isoforms were evident on the PMs of some pancreatic cancer cells, whereas others displayed minimal localization on or near the PMs. Well-differentiated BXPC3 cells, which have been described as the least invasive of the three cell lines used, 28 displayed far less prominent PM staining of the v-ATPase a3 isoform (Figure 2a ) than that found on Panc-1 cells (Figure 2b) . Similar to the a3 isoform, the soluble V 1 E isoform showed little PM localization (Figure 2c ) in BXPC3 cells. To further characterize these differences, colocalization
The v-ATPase in pancreatic cancer C Chung et al The v-ATPase in pancreatic cancer C Chung et al with E-cadherin was performed. BXPC3 cells, as described previously, showed faint E-cadherin expression when plated at low density (data not shown). In culture conditions approaching confluence, E-cadherin was discernible at sites of cell-to-cell contact (Figure 2d, arrows) , and showed no discernible overlap with V 1 E. In contrast, the leading edge of Panc-1 cells exhibited PM V 1 E staining (Figure 2e ) that overlapped with E-cadherin labeling on PMs (Figure 2f , arrows), but not at cellular junctions (Figure 2f , arrowheads).
(Additional high magnification images of V 1 E and E-cadherin labeling in Panc-1 cells are included in Supplementary  Figure 2 .) Staining for V 1 E and epidermal growth factor receptor in Panc-1 cells (Figure 2g and h) further showed that the v-ATPase is present on PMs (arrows). The hypoxia mimetic cobalt chloride 200 mM did not appear to increase the degree of v-ATPase labeling on PMs in Panc-1 cells (data not shown). Thus, the localization of the v-ATPase on PMs may reflect the functional ability to acidify local peri-cellular domains and contribute to the invasive phenotype of pancreatic cancer cells. Specific regions of cancer cells reflecting the leading edge or invasive front are responsible for focal protease release required for matrix degradation and cell invasion. 29 We investigated whether the v-ATPase colocalizes with other proteins that are know to reside in the leading edge. Cortactin is a prominent tyrosine kinase substrate that produces an actin assembly complex required for actin-based protrusions at the leading edge and directs MMP release at invasion sites. 20, 21, 30 In Panc-1 cells, V 1 E labeling (Figure 3a The v-ATPase in pancreatic cancer C Chung et al Cortactin localized to well-defined patches at the PM ( Figure  3b ). Double-labeling studies showed that the v-ATPase V 1 E subunit was located at or adjacent to regions of cortactin immunoreactivity (Figure 3c , arrow), with no overlap with cortactin staining on intracellular organelles (Figure 3c , inset, arrowhead). These results indicate that the v-ATPase on PMs co-distributes with known components of the cellular invasion apparatus. (Cortactin colocalization with another v-ATPase subunit, V 0 a3, is shown in Supplementary Figure 3. )
Pancreatic Cancer Cell-Derived MMP-9, but not MMP-2, Activities are Decreased with V-ATPase Blockade To examine the functional effect of v-ATPases on MMP activities, zymography of CM was performed with chemical inhibitors and short-hairpin (sh)RNA-mediated knockdown of the v-ATPase. MMP-9 activity was present in the three pancreatic cancer cell lines examined. Incubation with concanamycin (50 nM) led to significantly decreased MMP-9 activity in each cell line; this effect was most evident in (Figure 4d ). These cells showed significantly decreased MMP-9 activity that corresponded to the extent of V 1 E subunit knockdown. These results indicate pancreatic cancer cells with PM localization of the v-ATPase are susceptible to MMP-9 activities that depend on v-ATPase function.
V-ATPase inhibition yielded different effects on MMP-2 activity. MMP-2 activity was evident in the CM of Panc-1 cells, but barely detectable in MiaPaCa and BXPC3 lines (data not shown). In Panc-1 cells, the intermediately active (66 kDa) zymogen and the fully active (62 kDa) protease forms (Figure 4e ) could be differentiated. V-ATPase inhibition increased the most active forms of MMP-2 significantly more than under control conditions (Po0.001). Similar findings on MMP-2 activation were obtained using the related v-ATPase inhibitor, bafilomycin (50 nM), (Supplementary Figure 4 ). These results point to the different regulation and activation of MMP-2 versus MMP-9 precursor The v-ATPase in pancreatic cancer C Chung et al forms, and are consistent with a previous report on enhanced MMP-2 activities in melanoma cells treated with bafilomycin. 31 
Invasion and Cellular Degradation are V-ATPase Dependent
The functional effects of v-ATPase inhibition on cell invasion and migration were assessed. An agar-based assay showed that MiaPaCa cells were able to invade and this was inhibited in the presence of concanamycin (Figure 5, top) . Furthermore, concanamycin treatments also inhibited migration across a wound ( Figure 5, bottom; Po0.05) , with 21.9 and 35.1% greater diameter compared with controls under low and high glucose conditions, respectively. Panc-1 cells showed no differences in invasion in the presence of concanamycin (data not shown), a finding that may reflect the complex effects of concanamycin treatment on MMP activities: decreased MMP-9, but increased MMP-2 active isoforms.
DISCUSSION
This study illustrated that the cellular distribution of v-AT-Pase in human pancreatic cancer tissues may influence cancer cell activity as polarity is lost and expression was increased with advancing malignant features. In fact, striking differences in v-ATPase polarity and staining intensity distinguished early from advanced PanIN lesions. Invasive pancreatic cancers and metastatic lesions meanwhile showed uniformly diffuse and intense v-ATPase staining. These findings indicate that elevated expression and loss of v-AT-Pase polarity may be key steps in modulating the tumor microenvironment, thereby providing a clinical correlate to previous in vitro work in breast cancer cells that identified v-ATPase expression as a marker of cancer cell aggressiveness. 11 A previous study in human pancreatic cancer specimens compared mRNA levels and immunolabeling of the v-ATPase V 0 c subunit in PDAC in relation to precursor lesions and benign cystic tumors. 32 This study indicated that the mRNA levels of this subunit were increased in PDAC eightfold over normal pancreas. Similar to the results reported here, the intensity of v-ATPase expression was highest in PDAC. The absence of positive staining in non-invasive cancers or in benign cystic neoplasms in this previous study is a notable difference from our results. This study found that PanIN lesions showed prominent v-ATPase labeling with a clear loss of polarity that coincided with increasing malignant features. Our current results show a unique pattern to v-ATPase (V 1 E subunit) labeling within PDAC precursors, which suggests an early role for v-ATPase function in cancer cell homeostasis and invasive capacity as corroborated by previous literature. 11, 19, 33 Future evaluation of v-ATPase expression in human cancer sections using standardized antibodies and techniques may be necessary to resolve these differences.
Other studies have shown that the v-ATPase on PMs contributes to acidification of the extracellular space, which promotes invasive properties. 11, 34 Targeted inhibition of the The v-ATPase in pancreatic cancer C Chung et al V 0 c subunit led to diminished MMP-2 expression and reduced hepatocellular carcinoma growth in an animal model, indicating that the therapeutic potential of inhibiting the v-ATPase may be due in part to reducing MMP-2 activity. 34, 35 However, whether these findings are relevant to other types of cancers and other MMPs is unclear. We showed that the v-ATPase is present on PMs of Panc-1 cells; these cell lines have been described to have invasive potential in vivo. 28 In Panc-1 cells, the v-ATPase colocalizes with cortactin, a component of the cellular invasion apparatus implicated in focal MMP-9 release. 20, 21 Significantly, MMP-9 activity was reduced with v-ATPase blockade in three pancreatic cancer cell lines, but was least affected in BXPC3 cells, which showed little v-ATPase localization. Targeted inhibition of the V 1 E subunit using shRNA constructs confirmed these findings in Panc-1 cells. Thus, specific pancreatic cancer cells display v-ATPase PM localization and MMP-9 activities that are v-ATPase dependent.
In contrast to MMP-9, concanamycin and bafilomycin inhibition of the v-ATPase increased the fully active MMP-2 isoform. A potential explanation for this difference may be the differential regulation and activation of MMP-2 and -9 precursors. MT1-MMP, a cell surface activator of MMP-2, is rapidly and constitutively downregulated through a v-AT-Pase-dependent degradation process. 31, 36 V-ATPase blockade results in increased levels of active MT1-MMP on the cell surface, thereby amplifying MMP-2 activities, which is consistent with our findings. 31, 37 These findings indicate that The v-ATPase in pancreatic cancer C Chung et al potential targeting of the v-ATPase in cancer studies may have indirect (and unintended) effects on regulators of MMP activation that could enhance, rather than block, specific protease activities.
As MMP-2 activation with concanamycin treatments reflects the ability of intact intracellular degradation pathways that are v-ATPase dependent, these studies using chemical v-ATPase inhibitors do not allow us to discern the relative contributions of extracellular versus intracellular proton flux. Future experiments targeting the specific subunits associated with PM localization may help to provide additional evidence supporting a role for v-ATPase-mediated extracellular acidification.
Although we have shown that the v-ATPase can modulate MMP activities in cancer cells, this transporter can affect other cellular responses that may be relevant to cancer biology. For instance, v-ATPases may mediate resistance to chemotherapeutic agents. Tumor cells, when exposed to chemotherapeutic drugs, show transcriptional promoter activity that leads to the induction of specific v-ATPase levels. 38, 39 This induction precludes cancer cell apoptosis in response to chemotherapy, showing that v-ATPase expression may be a protective mechanism against chemically induced apoptosis. Combined application of chemotherapy and a v-ATPase inhibitor restored the ability of these agents to cause cancer cell apoptosis. 39 Thus, in addition to effects on MMP activities, targeting v-ATPases could also enhance the sensitivity of cancer cells to chemotherapeutics.
Accumulating evidence also points to the importance of cell surface v-ATPase function in non-malignant processes. In renal tubular epithelium, the v-ATPase is vital for urine acidification. Osteoclasts are enriched with specific v-ATPase isoforms at the ruffled border, which enables an optimal pH environment for proteases to degrade matrix. Endothelial cells adjacent to an induced wound display inducible and prominent PM v-ATPase localization and activity. 10 Endothelial cells obtained from diabetic rat models, however, display significantly reduced cell surface v-ATPase activity and show a functional impairment in migratory behavior. 40 These findings indicate that physiological and wound-repair processes likely require PM v-ATPase activity, possibly due to the effects on MMPs. In summary, v-ATPase staining of human pancreatic malignancy, ranging from PanIN lesions to PDAC, showed a marked loss of polarity and increased intensity with increasing tumor invasiveness. These changes were seen in PanIN lesions, suggesting a role for the v-ATPase in early stages of malignant transformation. Inhibiting v-ATPase function decreased MMP-9 activities, but increased MMP-2 activation in vitro. These results indicate that the v-ATPase plays a complex role in regulating MMPs and the pancreatic cancer phenotype. The v-ATPase in pancreatic cancer C Chung et al
